BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 37924937)

  • 1. Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles.
    Kumar V; Mahato RI
    Cancer Lett; 2023 Nov; 579():216462. PubMed ID: 37924937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
    Ghaedrahmati F; Esmaeil N; Abbaspour M
    Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of natural killer cells in pancreatic cancer.
    Peng X; Chen L; Jiao Y; Wang Y; Hao Z; Zhan X
    Oncol Lett; 2021 Sep; 22(3):647. PubMed ID: 34386069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cells in pancreatic cancer stroma.
    Fincham REA; Delvecchio FR; Goulart MR; Yeong JPS; Kocher HM
    World J Gastroenterol; 2021 Jun; 27(24):3483-3501. PubMed ID: 34239264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and prospects for use of cellular immunotherapy in pancreatic cancer.
    Tian J; Bai T; Zhang Z; Zhai X; Wang K; Gao X; Yan B
    J Cancer Res Ther; 2022 Dec; 18(7):1867-1875. PubMed ID: 36647944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment.
    Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A
    BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
    Phung CD; Tran TH; Kim JO
    Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects.
    Elahi R; Heidary AH; Hadiloo K; Esmaeilzadeh A
    Stem Cell Rev Rep; 2021 Dec; 17(6):2081-2106. PubMed ID: 34472037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
    Lin C; Zhang J
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
    Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
    Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
    Jiang D; Zhang J; Mao Z; Shi J; Ma P
    Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects and Advances in Adoptive Natural Killer Cell Therapy for Unmet Therapeutic Needs in Pediatric Bone Sarcomas.
    Bareke H; Ibáñez-Navarro A; Guerra-García P; González Pérez C; Rubio-Aparicio P; Plaza López de Sabando D; Sastre-Urgelles A; Ortiz-Cruz EJ; Pérez-Martínez A
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Advances in CAR-Based Solid Tumor Immunotherapy.
    Shin MH; Oh E; Kim Y; Nam DH; Jeon SY; Yu JH; Minn D
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.